CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Placebo for HydroxychloroquineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)


Name (Synonyms) Correlation
drug951 eculizumab Wiki 1.00
drug622 Placebo for Azithromycin Wiki 1.00
drug83 Azithromycin (Azithro) Wiki 1.00
drug361 Hydroxychloroquine (HCQ) Wiki 0.58

Correlated MeSH Terms (7)


Name (Synonyms) Correlation
D055370 Lung Injury NIH 0.32
D011024 Pneumonia, Viral NIH 0.17
D055371 Acute Lung Injury NIH 0.16
D013577 Syndrome NIH 0.15
D012127 Respiratory Distress Syndrome, Newborn NIH 0.15
D012128 Respiratory Distress Syndrome, Adult NIH 0.13
D011014 Pneumonia NIH 0.08

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19

The purpose of this study is to evaluate the efficacy of hydroxychloroquine (HCQ) and azithromycin (Azithro) to prevent hospitalization or death in symptomatic adult outpatients with COVID-19 caused by SARS-CoV-2 infection.

NCT04358068 COVID-19 SARS-CoV 2 Drug: Hydroxychloroquine (HCQ) Drug: Azithromycin (Azithro) Drug: Placebo for Hydroxychloroquine Drug: Placebo for Azithromycin

Primary Outcomes

Description: Hospitalization is defined as requiring at least 24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address needs during the COVID-19 pandemic. Evaluation at a hospital or similar facility with less than 24 hours of acute care is not considered a hospitalization.

Measure: Proportion of participants who died from any cause or were hospitalized

Time: Measured during the 21-day period from and including the day of the first (confirmed) dose of study treatment

Secondary Outcomes

Measure: Proportion of participants who died from any cause

Time: Measured during the 21-day period from and including the day of the first (confirmed) dose of study treatment

Measure: Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic

Time: Measured during the 21-day period from and including the day of the first (confirmed) dose of study treatment

Description: Hospitalization is defined as requiring at least 24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address needs during the COVID-19 pandemic. Evaluation at a hospital or similar facility with less than 24 hours of acute care is not considered a hospitalization.

Measure: Proportion of participants who died from any cause or were hospitalized through the end of follow-up

Time: Measured during the 24-week period from and including the day of the first (confirmed) dose of study treatment

Measure: Proportion of participants who prematurely discontinue study treatment due to an adverse event

Time: Measured through Day 7

Measure: Proportion of participants who had any cardiac adverse events

Time: Measured from start of study treatment through Day 20

Description: Defined as the last day in the participant's daily diary card on which a temperature greater than 100.4°F was recorded or a potentially antipyretic drug, such as acetaminophen or ibuprofen, was taken.

Measure: Duration of fever

Time: Measured through Day 20

Description: Defined as the last day in the participant's daily diary card on which a moderate or worse symptom was recorded

Measure: Duration of symptoms associated with COVID-19 disease

Time: Measured through Day 20

Description: Defined as the sum of scores for the targeted symptoms (defined in the protocol) in the participant's daily diary record (each individual symptom is scored from 0 to 3).

Measure: Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time

Time: Measured through Day 20

Measure: Time to self-reported return to usual (pre-COVID) health.

Time: Measured through Day 20

Measure: SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset

Time: Measured at entry, Day 6, and Day 20

Measure: SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset

Time: Measured at entry, Day 6, and Day 20


No related HPO nodes (Using clinical trials)